1 week Ago By ABMN Staff
Barclays PLC cut its stake in shares of Legend Biotech Co. ( NASDAQ:LEGN – Free Report ) by 21.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The firm owned 126,571 shares of the company’s stock after selling 33,779 shares during the period. Barclays PLC owned approximately 0.07% of Legend Biotech worth $4,120,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Legend Biotech by 12.
9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 7,324 shares of the company’s stock valued at $238,000 after buying an additional 835 shares in the last quarter.
Aigen Investment Management LP lifted its holdings in shares of Legend Biotech by 19.6% during the 4th quarter. Aigen Investment Management LP now owns 7,363 shares of the company’s stock valued at $240,000 after purchasing an additional 1,206 shares in the last quarter.
Rhumbline Advisers grew its position in shares of Legend Biotech by 5.9% in the 4th quarter. Rhumbline Advisers now owns 27,638 shares of the company’s stock valued at $899,000 after purchasing an additional 1,544 shares during the period.
Signaturefd LLC grew its position in shares of Legend Biotech by 1,052.7% in the 4th quarter. Signaturefd LLC now owns 1,729 shares of the company’s stock valued at $56,000 after purchasing an additional 1,579 shares during the period.
Finally, China Universal Asset Management Co. Ltd. increased its stake in Legend Biotech by 10.
2% during the 4th quarter. China Universal Asset Management Co. Ltd.
now owns 17,320 shares of the company’s stock worth $564,000 after purchasing an additional 1,609 shares in the last quarter. Institutional investors own 70.89% of the company’s stock.
Wall Street Analyst Weigh In A number of research analysts recently issued reports on LEGN shares. Guggenheim reiterated a “neutral” rating on shares of Legend Biotech in a report on Wednesday, March 12th. Piper Sandler reiterated an “overweight” rating and issued a $78.
00 price objective on shares of Legend Biotech in a report on Monday, December 30th. Morgan Stanley decreased their target price on shares of Legend Biotech from $82.00 to $80.
00 and set an “overweight” rating for the company in a research report on Monday, March 17th. Royal Bank of Canada reissued an “outperform” rating and set a $84.00 price target on shares of Legend Biotech in a research report on Tuesday, April 22nd.
Finally, HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Legend Biotech in a report on Wednesday, April 16th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock.
According to MarketBeat, Legend Biotech currently has an average rating of “Moderate Buy” and an average target price of $78.82. Legend Biotech Trading Up 0.
1 % LEGN opened at $34.28 on Monday. The firm has a market capitalization of $6.
30 billion, a PE ratio of -36.08 and a beta of 0.21.
The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.
90. Legend Biotech Co. has a fifty-two week low of $29.
27 and a fifty-two week high of $60.87. The company’s 50-day moving average is $34.
76 and its 200 day moving average is $37.11. Legend Biotech ( NASDAQ:LEGN – Get Free Report ) last posted its quarterly earnings data on Tuesday, March 11th.
The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.
46. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.
69%. The firm had revenue of $186.50 million for the quarter, compared to the consensus estimate of $179.
00 million. During the same period in the previous year, the firm earned ($0.40) EPS.
The business’s revenue for the quarter was up 134.6% compared to the same quarter last year. As a group, research analysts predict that Legend Biotech Co.
will post -1.31 earnings per share for the current fiscal year. Legend Biotech Company Profile ( Free Report ) Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). Featured Articles Want to see what other hedge funds are holding LEGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Legend Biotech Co.
( NASDAQ:LEGN – Free Report ). Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter .
.
